MCID: BRN034
MIFTS: 24

Brain Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Meningioma

MalaCards integrated aliases for Brain Meningioma:

Name: Brain Meningioma 38 12 14
Intracranial Meningioma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060106

Summaries for Brain Meningioma

MalaCards based summary : Brain Meningioma, also known as intracranial meningioma, is related to childhood brain meningioma and back pain, and has symptoms including headache and seizures. An important gene associated with Brain Meningioma is CASP9 (Caspase 9). The drugs Thrombin and Coagulants have been mentioned in the context of this disorder. Affiliated tissues include Brain, brain and endothelial.

Related Diseases for Brain Meningioma

Diseases related to Brain Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 childhood brain meningioma 11.8
2 back pain 9.5
3 calvarial hyperostosis 9.5
4 hyperostosis 9.5
5 cervicitis 9.5
6 cerebritis 9.5
7 radiculopathy 9.5
8 hypersensitivity syndrome, carbamazepine-induced 9.5 CASP9 GFAP
9 bronchiolitis obliterans 9.2 CASP9 GFAP

Graphical network of the top 20 diseases related to Brain Meningioma:



Diseases related to Brain Meningioma

Symptoms & Phenotypes for Brain Meningioma

UMLS symptoms related to Brain Meningioma:


headache, seizures

Drugs & Therapeutics for Brain Meningioma

Drugs for Brain Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved Phase 4
2 Coagulants Phase 4,Phase 3
3 Hemostatics Phase 4,Phase 3
4 Fibrin Tissue Adhesive Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
9 Antifibrinolytic Agents Phase 3
10 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
11 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
12 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
13 Nootropic Agents Phase 3,Phase 2,Early Phase 1
14 Central Nervous System Stimulants Phase 3,Phase 2
15 Dexmethylphenidate Hydrochloride Phase 3
16 Dopamine Agents Phase 3
17 Dopamine Uptake Inhibitors Phase 3
18 Neurotransmitter Uptake Inhibitors Phase 3
19
Hydroxyurea Approved Phase 2 127-07-1 3657
20
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
21
Verapamil Approved Phase 2 52-53-9 2520
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
26
Armodafinil Approved, Investigational Phase 2 112111-43-0
27
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
28 Piracetam Approved Phase 2 7491-74-9
29
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
30
Aldesleukin Approved Phase 2,Phase 1 85898-30-2, 110942-02-4
31
Carmustine Approved Phase 2,Phase 1 154-93-8 2578
32
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
Lenograstim Approved Phase 2,Phase 1 135968-09-1
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Everolimus Approved Phase 2 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
39
nivolumab Approved Phase 2 946414-94-4
40
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
41
Somatostatin Approved Phase 2 38916-34-6, 51110-01-1 53481605
42
Vatalanib Investigational Phase 2 212141-54-3 151194
43 Etiracetam Investigational Phase 2 33996-58-6
44
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Imatinib Mesylate Phase 2,Phase 1 123596
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 Edotreotide Phase 1, Phase 2
49
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
50 Dermatologic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 107)

id Name Status NCT ID Phase Drugs
1 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
2 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
3 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
4 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery Terminated NCT00104936 Phase 3
6 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
7 Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
8 Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
9 Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial. Unknown status NCT01795300 Phase 1, Phase 2
10 Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
11 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
12 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
13 Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
14 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
15 Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma Completed NCT00626730 Phase 2
16 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00348790 Phase 2 vatalanib
17 S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma Completed NCT00003590 Phase 2 hydroxyurea
18 Imatinib Mesylate in Treating Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
19 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
20 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
21 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
22 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
23 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
24 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
25 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
26 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
27 SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed NCT00004868 Phase 1, Phase 2 semaxanib
28 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
29 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
30 Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas Recruiting NCT02523014 Phase 2 vismodegib;GSK2256098
31 A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas Recruiting NCT02693990 Phase 1, Phase 2
32 Proton Radiation For Meningiomas and Hemangiopericytomas Recruiting NCT01117844 Phase 1, Phase 2
33 Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Recruiting NCT01849484 Phase 2
34 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
35 Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Recruiting NCT02847559 Phase 2
36 The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
37 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
38 Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma Active, not recruiting NCT00895622 Phase 2
39 Trabectedin for Recurrent Grade II/III Meningioma Active, not recruiting NCT02234050 Phase 2 Trabectedin
40 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
41 Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma Terminated NCT00972335 Phase 2 Everolimus;Bevacizumab
42 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
43 Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery Unknown status NCT02084927 Phase 1
44 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
45 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
46 Fluorescence Guided Resection of Brain Tumors Unknown status NCT00870779 Phase 1 5-aminolevulinic acid
47 Cellular Immunotherapy Study for Brain Cancer Completed NCT01144247 Phase 1 alloreactive CTL
48 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
49 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
50 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide

Search NIH Clinical Center for Brain Meningioma

Genetic Tests for Brain Meningioma

Anatomical Context for Brain Meningioma

MalaCards organs/tissues related to Brain Meningioma:

39
Brain, Endothelial, Bone, Testes, T Cells, Bone Marrow, Spinal Cord
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Brain Meningioma:
id Tissue Anatomical CompartmentCell Relevance
1 Brain Anterior Dura Mater Affected by disease

Publications for Brain Meningioma

Articles related to Brain Meningioma:

id Title Authors Year
1
Rare giant bilateral calvarial hyperostosis across the superior sagittal sinus secondary to brain meningioma: A case report. ( 24959261 )
2014
2
Carotid artery stenting in patients with brain meningioma. ( 24791910 )
2014
3
Brain meningioma with initial manifestation similar to cervical radiculopathy: a case report. ( 25028552 )
2014
4
Brain meningioma in a patient with complaints of low back pain and leg weakness. ( 23126500 )
2013
5
Surgical Resection of Twenty-Three Cases of Brain Meningioma. ( 24200893 )
2013
6
Brain meningioma invading and destructing the skull bone: replacement of the missing bone in vivo. ( 22933971 )
2011
7
Microscopic anatomy of the brain-meningioma interface. ( 18095106 )
2005
8
The occurrence of polyunsaturated aldehydes in choline-containing phosphoglycerides of a human brain meningioma. ( 6064623 )
1967

Variations for Brain Meningioma

Expression for Brain Meningioma

Search GEO for disease gene expression data for Brain Meningioma.

Pathways for Brain Meningioma

GO Terms for Brain Meningioma

Sources for Brain Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....